144 studies found for:    "AL amyloidosis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Radioimmunoimaging of AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
2 Suspended Trial of HDM/SCT Versus HDM + Bortezomib/SCT in AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Neupogen;   Procedure: Stem Cell Collection;   Procedure: Stem cell infusion
3 Active, not recruiting Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bendamustine;   Drug: Dexamethasone
4 Recruiting Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Venetoclax;   Drug: Dexamethasone
5 Not yet recruiting Daratumumab for the Treatment of Patients With AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: daratumumab
6 Active, not recruiting A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone
7 Completed Radioimmunoimaging of Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
8 Completed Allo SCT in Amyloidosis Non-interventional Study
Condition: AL Amyloidosis
Intervention:
9 Active, not recruiting Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Conditions: AL Amyloidosis;   Amyloidosis
Intervention: Other: non-interventional
10 Completed Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
11 Recruiting Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);   Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
12 Active, not recruiting Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Intervention: Drug: Pomalidomide and Dexamethasone
13 Suspended High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Device: High Cut-off Hemodialysis;   Drug: Chemotherapy
14 Recruiting The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: NEOD001;   Drug: Placebo
15 Active, not recruiting Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: NEOD001
16 Completed A Trial for Systemic Light-chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: BMDex
17 Recruiting Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
Conditions: Amyloidosis;   Primary Amyloidosis
Intervention:
18 Recruiting First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: Laboratory Biomarker Analysis
19 Completed A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
20 Recruiting Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Other: blood collection;   Other: bone marrow collection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.